Literature DB >> 9332912

Proposal for improved staging criteria for carcinoma of the esophagus and cardia.

F H Ellis1, G J Heatley, K Balogh.   

Abstract

OBJECTIVE: Current staging for carcinoma of the esophagus and cardia remains imprecise. In an effort to improve on presently accepted staging criteria, new and improved criteria were sought.
METHODS: A total of 408 specimens resected for carcinoma of the esophagus or cardia between January 1, 1970, and January 1, 1994, were available for analysis. Pathology reports were reviewed, and available histologic slides were examined microscopically. When necessary, paraffin blocks of excised specimens were recut for further pathologic evaluation. On the basis of these findings, tumors were staged according to the criteria of American Joint Committee on Cancer (AJCC). New criteria were established based on the WNM concept and staged accordingly. Survival rates based on these sets of criteria were calculated for each stage, and results were compared.
RESULTS: Because our previous studies had shown no advantage provided by the revised AJCC criteria compared with those originally proposed, we modified the WNM system by eliminating the subdivisions of Stage II, reducing the T categories by 1, T3 and T4 having shown no survival differences, and increasing the N categories by 1, depending on the number of nodes involved, e.g. NO = no positive nodes; N1 = 1-4 positive nodes, and N2-5 or more positive nodes. The resulting staging system and 5-year survival rates obtained thereby are as follows: Stage O (TO, is, 1 NO), 88.2%; Stage I (T1N1, T2NO), 50.3%; Stage II (T2N1, T3N0) 22.5%; Stage III (T3N1, any T N2), 10.7%; and Stage IV (M1) 0%.
CONCLUSIONS: A new staging scheme for carcinoma of the esophagus and cardia is proposed that provides better prognostic stratification of patients than existing ones.

Entities:  

Mesh:

Year:  1997        PMID: 9332912     DOI: 10.1016/s1010-7940(97)00178-4

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  7 in total

1.  Surgical management of esophageal carcinoma.

Authors:  Amit N Patel; John T Preskitt; Joseph A Kuhn; Robert F Hebeler; Richard E Wood; Harold C Urschel
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-07

2.  The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection.

Authors:  Harry H Yoon; Maliha Khan; Qian Shi; Stephen D Cassivi; Tsung-Teh Wu; J Fernando Quevedo; Patrick A Burch; Frank A Sinicrope; Robert B Diasio
Journal:  Mayo Clin Proc       Date:  2010-12       Impact factor: 7.616

3.  Long-term outcomes of extended proximal gastrectomy for oesophagogastric junctional tumours.

Authors:  Omar Khan; Steven Goh; Ben Byrne; Shaw Somers; Stuart Mercer; Simon Toh
Journal:  World J Surg       Date:  2011-10       Impact factor: 3.352

Review 4.  Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy.

Authors:  Kaushik Mukherjee; A Bapsi Chakravarthy; Laura W Goff; Wael El-Rifai
Journal:  Dig Dis Sci       Date:  2010-03-19       Impact factor: 3.199

5.  Lipid Peroxidation and Transforming Growth Factor-β1 Levels in Gastric Cancer at Pathologic Stages.

Authors:  Sefa Tüzün; Ahmet Fikret Yücel; Ahmet Pergel; Ahu Sarbay Kemik; Ozgür Kemik
Journal:  Balkan Med J       Date:  2012-09-01       Impact factor: 2.021

6.  Emerging aspects of oesophageal and gastro-oesophageal junction cancer histopathology - an update for the surgical oncologist.

Authors:  Ewen A Griffiths; Susan A Pritchard; Nicholas P Mapstone; Ian M Welch
Journal:  World J Surg Oncol       Date:  2006-11-21       Impact factor: 2.754

7.  Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome.

Authors:  Antoine Adenis; Emmanuelle Tresch; Sylvain Dewas; Olivier Romano; Mathieu Messager; Eric Amela; Stéphanie Clisant; Andrew Kramar; Christophe Mariette; Xavier Mirabel
Journal:  BMC Cancer       Date:  2013-09-06       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.